Pharmena SA
WSE:PHR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmena SA
Total Current Liabilities
Pharmena SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmena SA
WSE:PHR
|
Total Current Liabilities
zł719k
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
4
|
4Mass SA
WSE:4MS
|
Total Current Liabilities
zł12.9m
|
CAGR 3-Years
61%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
H
|
Harper Hygienics SA
WSE:HRP
|
Total Current Liabilities
zł129.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Miraculum SA
WSE:MIR
|
Total Current Liabilities
zł14m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
Pharmena SA
Glance View
PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. The company is headquartered in Lodz, Woj. Lodzkie and currently employs 24 full-time employees. The company went IPO on 2008-08-25. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
See Also
What is Pharmena SA's Total Current Liabilities?
Total Current Liabilities
719k
PLN
Based on the financial report for Sep 30, 2025, Pharmena SA's Total Current Liabilities amounts to 719k PLN.
What is Pharmena SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-20%
Over the last year, the Total Current Liabilities growth was 0%. The average annual Total Current Liabilities growth rates for Pharmena SA have been -65% over the past three years , -39% over the past five years , and -20% over the past ten years .
